Beijing Beilu Pharmaceutical (300016.SZ) obtains the drug registration certificate for sildenafil citrate orally disintegrating tablets.

Beijing Beilu Pharmaceutical (300016.SZ) announced that the company has recently received the "Drug Registration Certificate" for the sildenafil citrate orally disintegrating tablets approved by the National Medical Products Administration. Sildenafil is a selective inhibitor of phosphodiesterase type 5, used to treat erectile dysfunction, with advantages such as fast onset of action and definite efficacy. The sildenafil citrate orally disintegrating tablets is an iteration form of sildenafil developed by Pfizer, approved for import in China in 2019. The sildenafil citrate orally disintegrating tablets do not require water to be taken, can disintegrate in the mouth in a few seconds, have a fast onset of action, and can meet the needs of patients for convenient, fast-acting, and discreet oral medications, providing patients with more flexible and diverse options for medication.